Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBSep 7, 2013 · In an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Breast Cancer | Oncology News & Insights | Targeted Oncology
WEBSep 11, 2024 · Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting. Jordyn Sava. July 12th 2024. In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Defining Unresectable and Advanced HCC - Targeted Oncology
WEBJul 20, 2021 · After the approval of sorafenib, we had numerous negative studies, until the REFLECT study. This transcript has been edited for clarity. Richard S. Finn, MD defines unresectable or advanced hepatocellular carcinoma by discussing venous invasion, extrahepatic spread, and progression after locoregional treatments.
Continuing Osimertinib Treatment After Progression Prolongs …
WEBJan 25, 2019 · The investigators said that continuing osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients. They suggested that further study will be needed, especially given the increasing role for osimertinib in the treatment of EGFR -mutant advanced NSCLC. Reference:
FDA Approves Capmatinib in MET Exon 14+ Metastatic Non-Small …
WEBMay 6, 2020 · The FDA granted approval to capmatinib (Tabrecta) for adult patients with metastatic non–small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. 1 Capmatinib was previously granted Priority Review by the FDA in February 2020 for this indication based on results from the GEOMETRY ...
Docetaxel Continues to Show Profound Benefits in Prostate Cancer
WEBJan 14, 2017 · In the larger STAMPEDE trial (2962 patients), adding docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer. The median overall survival (OS) was 81 months with docetaxel plus standard of care (hormonal therapy with or …
IGHV and TP53 Remain Important Prognostic CLL Biomarkers
WEBSep 9, 2021 · IGHV and TP53 remain clinical prognostic importance in patients with chronic lymphocytic leukemia (CLL), despite many prognostic markers for chemoimmunotherapy losing their clinically relevance in the context of targeted therapies for patients, according to a debate that took place during the 2021 SOHO Annual Meeting. 1,2. Although several markers of CLL activity and growth, notably IGHV and ...
AML - Targeted Oncology
WEBSELECT-AML-1 Trial of Tamibarotene Combo in AML Discontinues Enrollment. By Jordyn Sava. August 13th 2024. Following a futility analysis, the phase 2 SELECT-AML-1 trial of tamibarotene combined with venetoclax and azacitidine in newly diagnosed RARA-overexpressed acute myeloid leukemia will discontinue enrollment.
Next Generation Androgen Receptor Inhibitors - Targeted Oncology
WEBNov 10, 2021 · There are currently 4 approved androgen receptor pathway inhibitors in the United States: 3 anti-androgens—apalutamide, enzalutamide, and darolutamide—and an androgen receptor pathway inhibitor, abiraterone acetate. The efficacy of these agents, while rarely studied head-to-head, appears remarkably …
Repotrectinib Demonstrates Early Clinical Activity in ROS1
WEBJan 31, 2021 · The EXP-1 cohort includes 55 patients with ROS1 TKI–naïve ROS1 fusion–positive advanced NSCLC. Patients in this cohort are a median of 58 years old (range, 30-76). Sixty percent of the population has an ECOG performance status of 1, and 20% had prior chemotherapy use. In phase 1 of the TRIDENT-1 study, this cohort achieved an ORR of 86% ...
Skip to content